Skip to main content Accessibility help
×
Home

Dual silencing of type 1 insulin-like growth factor and epidermal growth factor receptors to induce apoptosis of nasopharyngeal cancer cells

  • Y-L Yuan (a1), X-H Zhou (a2), Jian Song (a2), X-P Qiu (a3), Jun Li (a2) and L-F Ye (a2)...

Abstract

Objective:

The epidermal growth factor receptor (EGFR) and type 1 insulin-like growth factor receptor (type 1 IGF receptor or IGF1R) have played an important role in the growth and apoptosis of cancer. The RNA interference (RNAi) technique can suppress gene expression, but the effects of dual silencing of EGFR and type 1 IGF receptor have not been well understood.

Methods:

pU6-EGFR-shRNA-1, pU6-EGFR-shRNA-2, pU6-IGF1R-shRNA-1 and pU6-IGF-1R-shRNA-2 plasimd vectors were transfected to the nasopharyngeal cancer cells. Seven groups were selected for the study. The protein and downstream protein expression were assessed by Western blot. Apoptosis was determined via flow cytometry. Meanwhile, chemosensitivity of nasopharyngeal cancer cell lines transfeced to chemotherapeutic drugs were carried out by MTT.

Results:

In dual silencing of EGFR and IGF-1R, the protein expression much more was decreased than single silencing of EGFR or IGF-1R, but the cell apoptosis much more is increased than single silencing EGFR or IGF-1R. Dual silencing of EGFR and IGF-1R enhanced chemosensitivity to anticancer drugs, compared with single silencing of EGFR or IGF-1R.

Conclusion:

Dual silencing of EGFR and IGF-1R are capable of suppressing EGFR and IGF-1R expression of the nasopharyngeal cancer cell and can promote apoptosis and increase the cell sensitivity of anticancer drug. The dual silencing of genes RNAi technique is significantly better than a single gene.

Copyright

Corresponding author

Address for correspondence: Dr Jian Song, Department of Anatomy, Wuhan University School of Medicine, Wuhan 430071, PR China E-mail: y030612_030912_04021@126.com

References

Hide All
1 Parkin, DM, Pisani, P, Ferlay, J. Global cancer statistics. CA Cancer J Clin 1999;49:3364
2 Su, CK, Wang, CC. Prognostic value of Chinese race in nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 2002;54:752–8
3 Tong, AW, Zhang, YA, Nemunaitis, J. Small interfering RNA for experimental cancer therapy. Curr Opin Mol Ther 2005;7:114–24
4 Bohula, EA, Salisbury, AJ, Sohail, M, Playford, MP, Riedemann, J, Southern, EM et al. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem 2003;278:15991–7
5 Xiangbai, Wu, Yongzhi, Deng, Guobin, Wang, Kaixiong, Tao. Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells. J Surg Res 2006;27:18
6 Tuschl, T. Expanding small RNA interference. Nat Biotechnol 2002;20:446–8
7 Zhang, M, Zhang, X, Bai, CX, Song, XR, Chen, J, Gao, L et al. Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer. Genet Vaccines Ther 2005;3:5
8 Lee, YJ, Imsumran, A, Park, MY, Kwon, SY, Yoon, HI, Lee, JH et al. Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway. Lung Cancer 2007;55(3):279–86
9 Jackson, AL, Bartz, SR, Schelter, J, Kobayashi, SV, Burchard, J, Mao, M et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003;21:635–7
10 Brummelkamp, TR, Bernards, R, Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550–3
11 Oldak, M, Malejczyk, J. Signal transduction mechanisms induced by epidermal growth factor receptor (EGFR) and their role in apoptosis regulation [in Polish]. Postepy Hig Med Dosw 1999;53:315
12 Harari, PM, Huang, SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001;49:427
13 Shawver, LK, Slamon, D, Ullrich, A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002;1:117

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed